Insilico agrees on $66M deal to split rights for preclinical NLRP3 inhibitor with new Chinese biotech

AI-powered drug developer Insilico Medicine is set for a $10 million upfront payment from a fresh-faced Chinese biotech for half of the rights to a brain-penetrant NLRP3 inhibitor.